Additional file 1 of Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study

Additional file 1: Supplementary Table 1. Additional HBeAg seroconversion during long-term follow-up. Supplementary Table 2. HBeAg seroclearance in different nucleos(t)ide analogues with and without hepatic steatosis (HS). Supplementary Table 3. Comparison of baseline characteristics and treatment response among patients with different degrees of histological steatosis. Supplementary Table 4. Baseline clinical characteristics among patients with lamivudine (LAM), entecavir (ETV) and telbivudine (LdT) treatment*.